- Home
- ROIV vs CELH Comparison
ROIV vs CELH Comparison
Compare ROIV & CELH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ROIV
- CELH
- Stock Information
- Founded
- ROIV 2014
- CELH 2004
- Country
- ROIV United Kingdom
- CELH United States
- Employees
- ROIV N/A
- CELH N/A
- Industry
- ROIV Biotechnology: Pharmaceutical Preparations
- CELH Beverages (Production/Distribution)
- Sector
- ROIV Health Care
- CELH Consumer Staples
- Exchange
- ROIV Nasdaq
- CELH Nasdaq
- Market Cap
- ROIV 8.4B
- CELH 7.5B
- IPO Year
- ROIV N/A
- CELH N/A
- Fundamental
- Price
- ROIV $10.64
- CELH $36.77
- Analyst Decision
- ROIV Buy
- CELH Buy
- Analyst Count
- ROIV 4
- CELH 17
- Target Price
- ROIV $17.50
- CELH $47.41
- AVG Volume (30 Days)
- ROIV 6.4M
- CELH 6.8M
- Earning Date
- ROIV 05-29-2025
- CELH 05-06-2025
- Dividend Yield
- ROIV N/A
- CELH N/A
- EPS Growth
- ROIV N/A
- CELH N/A
- EPS
- ROIV N/A
- CELH 0.32
- Revenue
- ROIV $122,585,000.00
- CELH $1,329,198,000.00
- Revenue This Year
- ROIV N/A
- CELH $42.37
- Revenue Next Year
- ROIV N/A
- CELH $17.56
- P/E Ratio
- ROIV N/A
- CELH $113.20
- Revenue Growth
- ROIV 140.04
- CELH N/A
- 52 Week Low
- ROIV $8.73
- CELH $21.10
- 52 Week High
- ROIV $13.06
- CELH $98.85
- Technical
- Relative Strength Index (RSI)
- ROIV 47.30
- CELH 57.71
- Support Level
- ROIV $11.02
- CELH $32.36
- Resistance Level
- ROIV $11.77
- CELH $36.16
- Average True Range (ATR)
- ROIV 0.33
- CELH 1.77
- MACD
- ROIV -0.02
- CELH -0.24
- Stochastic Oscillator
- ROIV 28.93
- CELH 64.85
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
About CELH Celsius Holdings Inc.
Celsius Holdings plays in the energy drink subsegment of the global nonalcoholic beverage market, with 96% of revenue concentrated in North America. Celsius' products contain natural ingredients and a metabolism-enhancing formulation, appealing to fitness and active lifestyle enthusiasts. The firm's portfolio includes its namesake Celsius Originals beverages, Celsius Essentials line (containing aminos), and Celsius On-the-Go powder packets. Celsius dedicates its efforts to branding and innovation, while it utilizes third parties for the manufacturing, packaging, and distribution of its products. In 2022, Celsius forged a 20-year distribution agreement with PepsiCo, which holds an 8.5% stake in the business.